Literature DB >> 8589182

Foscarnet-resistant multidermatomal zoster in a patient with AIDS.

A M Fillet1, B Visse, E Caumes, B Dumont, M Gentilini, J M Huraux.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589182     DOI: 10.1093/clinids/21.5.1348

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

Review 1.  Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.

Authors:  A Sauerbrei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

2.  A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame.

Authors:  R Sahli; G Andrei; C Estrade; R Snoeck; P R Meylan
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate.

Authors:  Anne-Kathrin Brunnemann; Kathrin Bohn-Wippert; Roland Zell; Andreas Henke; Martin Walther; Oliver Braum; Gregor Maschkowitz; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

Review 4.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

Review 5.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

Review 6.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.